We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Name | Symbol | Market | Type |
|---|---|---|---|
| Roche Holdings Ltd AG (QX) | USOTC:RHHBY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.06 | 0.14% | 43.42 | 43.02 | 43.57 | 43.48 | 43.08 | 43.37 | 10,152,314 | 21:00:02 |
From Mar 2023 to Mar 2025
By David Sachs
Roche aims to buy Carmot Therapeutics, a California-based pharmaceutical firm developing drugs to treat obesity and diabetes.
The Swiss pharmaceutical company said it has entered an agreement to acquire the private company for $2.7 billion with additional payments of up to $400 million based on drug-development milestones.
The deal would give Roche access to Carmot's research-and-development portfolio, including all clinical and pretrial assets, Roche said. The portfolio includes drugs in development to treat obesity as well as type-1 and type-2 diabetes, Roche said.
Roche expects to close the transaction in the first quarter of 2024.
Write to David Sachs at david.sachs@wsj.com
(END) Dow Jones Newswires
December 04, 2023 01:32 ET (06:32 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Roche (QX) Chart |
1 Month Roche (QX) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
